Hold Dr. Reddys Laboratories; target of Rs 2660: Edelweiss

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Edelweiss' research report on Dr. Reddys Laboratories

Dr. Reddys Laboratories’ (DRRD) Q4FY17 earnings continued to be weak after the unsustainable gross margin spike in Q3FY17. Revenue, EBITDA and adjusted PAT tumbled 5%, 25% and 4% YoY, respectively, hit by supply constraints and pricing pressure in US. Including the recent limited competition gVytorin launch, DRRD expects to launch >10 US products during FY18.

Outlook

We expect the base business to remain under pressure, unless there are key launches of gCopaxone and gNuvaring built in estimates. Maintain ‘HOLD’ with INR 2,660 (18x FY19E EPS) target price.

For all recommendations, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Read More